Table 1.
Baseline characteristics
| Number of patients included | 168 |
| Median age, years (IQR) | 67 (61–73) |
| Male gender | 65% |
| Smoking status | Current: 19% |
| Former: 79% | |
| Never: 2% | |
| Smoking history: median pack years (IQR) | 48 (30–60) |
| Body mass index (kg/m2), median (IQR) | 26.0 (23.0–29.1) |
| GOLD stage, % of patients | |
| 1 | 8.70% |
| 2 | 40.50% |
| 3 | 32.90% |
| 4 | 17.90% |
| GOLD risk class, % of patients | |
| A | 4.00% |
| B | 51.40% |
| C | 8.70% |
| D | 35.80% |
| Mean FEV1, % predicted (range) | 51 (16–115) |
| Mean SGRQ score (range) | 42 (5–83) |
| Mean mMRC score (range) | 2 (0–4) |
| 6MWD in metres, median (IQR) | 418 (360–506) |
| BODE index, median (IQR) | 3 (1–4) |
| Pharmacotherapy for COPD, % of patients | |
| SAMA | 13% |
| SABA | 39% |
| LAMA | 86% |
| LABA | 87% |
| ICS | 54% |
| Systemic corticosteroids | 8% |
| Mucolytics | 10% |
| LTOT, % of patients | 26% |
| CPAP, % of patients | 7% |
| NIV, % of patients | 9% |
| Supervised rehabilitation in the past, % of patients | 31% |
| Volume reduction therapy, % of patients | 7% |
| Comorbidities, % of patients | |
| Arterial hypertension | 44% |
| Coronary artery disease | 18% |
| Congestive heart failure | 6% |
| Myocardial infarction | 9% |
| Pulmonary hypertension | 3% |
| Malignancy | 9% |
| Diabetes | 10% |
| Renal failure | 8% |
| Psychiatric disease | 9% |
| Influenza vaccination applied, % of patients | 71% |
| Pneumococcal vaccination applied, % of patients | 44% |
| Charlson comorbidity index, median (IQR) | 1 (1–2) |
CPAP, continuous positive airway pressure; FEV1, forced expiratory volume in 1 s; GOLD, Global Initiative for Obstructive Lung Disease; ICS, inhalative corticosteroids; IQR, interquartile range; LABA, long‐acting beta agonists; LAMA, long‐acting muscarinic antagonists; LTOT, long‐term oxygen therapy; NIV, noninvasive ventilation; SABA, short‐acting beta agonists; SAMA, short‐acting muscarinic antagonists.